Is Statin Use Associated with Better COVID-19 Hospitalization Outcomes?
BACKGROUND AND PURPOSE:
Statins may be able to mitigate myocardial injury and thrombotic events due to anti-inflammatory and antithrombotic properties
Gupta et al. (Nature Communications, 2021) investigated the hypothesis that statins may mitigate adverse COVID-19 consequences
Retrospective cohort study (between February 1st and May 12th, 2020)
Hospitalized with COVID-19
Antecedent statin use
Data derived from electronic medical record
A multivariable logistic regression model was used to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications
In-hospital mortality within 30 days
Invasive mechanical ventilation within 30 days of admission
2626 total patients patients
Antecedent statin users: 36.2%
1296 patients ascertained for 1:1 propensity-score matching
648 statin users | 648 non-statin users
In the propensity-matched cohort, statin use was significantly associated with lower odds of in-hospital mortality within 30 days
Occurrence in statin users: 14.8%
Occurrence in non-statin users: 26.5%
Odds ratio 0.47 (95% CI, 0.36 to 0.62; p < 0.001)
Patients on statins had
Lower WBC count at presentation: 7.6 vs 8.1; p < 0.01
Lower CRP levels: 100.0 vs 120.7; p < 0.01
No significant differences for the following additional outcomes
Invasive mechanical ventilation | Vasopressor use | Renal replacement therapy | Length of stay between the groups
Antecedent statin use among patients hospitalized for COVID-19 is associated with a reduction in in-hospital mortality
The authors conclude
In this large analysis from a quaternary academic medical institution in an epicenter of the COVID-19 pandemic, we demonstrated that antecedent statin use was associated with significantly lower rates of in-hospital mortality within 30 days
These results indicate the important need for randomized controlled trials evaluating the benefits of statin therapy in patients affected by COVID-19
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan